Trial intelligence / Profile preview

BVD for relapsed or refractory multiple myeloma

2010-020072-33Phase 2Active

Sponsor: Azienda Ospedaliero-Universitaria delle Marche
Start: Dec 2010
Modality: Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Small Molecules
Countries: 1

Overview

Phase 2, open-label, single-arm trial of bendamustine, bortezomib and dexamethasone in multiple myeloma (MM), sponsored by Azienda Ospedaliero-Universitaria delle Marche. Primary endpoint: Objective response rate after 4 cycles. Started Dec 2010; status: active.

Drugs

bendamustinebortezomibdexamethasone

Conditions

multiple myeloma (MM)

Beyond the preview

Go deeper on 2010-020072-33.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2010-020072-33.